Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen I. Fernandez(Yale University), David L. Rimm(Yale University), Esther Yoon(Cleveland Clinic Florida), Lajos Pusztai(Yale University), Kamaljeet Singh, T. Rinda Soong(University of Pittsburgh Medical Center), Julie M. Jorns(Medical College of Wisconsin), Krisztina Hanley(Emory University), Emily Reisenbichler(Saint Louis University), Oluwole Fadare(University of California, San Diego), Olivia L. Snir(Oregon Health & Science University), Andrew M. Bellizzi(University of Iowa), Malini Harigopal, Shi Wei(University of Alabama at Birmingham), Mirna Podoll(Breast Cancer Research Foundation), Hannah Y. Wen(Memorial Sloan Kettering Cancer Center), Mary Ann Sanders(University of Louisville), Matthew Liu(Yale University), Amy Ly(Washington University in St. Louis), Serena Wong(Yale University), M. Gabriela Kuba(Memorial Sloan Kettering Cancer Center), Jane Brock(Brigham and Women's Hospital), Kimmie Rabe(University of Minnesota)
Cited by 347
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k